Table 2.

Associations of HPV16, high-risk (HR) oncogenic HPV, and other α HPV types with risks of esophageal cancer and histologic type

Cases (n = 125)Controls (n = 371)aAdjusted modelb
All esophageal cancersα HPV typeN (%)N (%)ORa (95% CI)PPermutated Pd
HPV161 (0.8)6 (1.6)0.54 (0.10–4.84)0.58>0.999
HR-HPVsc excluding HPV168 (6.4)18 (4.9)1.21 (0.49–2.99)0.68>0.999
NonHR HPV types16 (12.8)36 (9.7)1.47 (0.77–2.81)0.240.801
Any α HPV23 (18.4)53 (14.3)1.39 (0.78–2.48)0.260.823
ESCC
α HPV typeCases (n = 28)Controls (n = 83)ORa (95% CI)PPermutated Pd
HPV160 (0)1 (1.2)>0.999
HR-HPVsc excluding HPV163 (10.7)1 (1.2)10.52 (1.01–108.5)0.0480.236
Non-HR HPV types4 (14.3)11 (13.3)1.68 (0.41–6.91)0.48>0.999
Any α HPV6 (21.4)13 (15.7)2.21 (0.61–8.05)0.230.772
Esophageal cancer: adenocarcinoma
α HPV typeCases (n = 80)Controls (n = 238)ORa (95% CI)PPermutated Pd
HPV161 (1.3)5 (2.1)0.60 (0.10–5.85)0.66>0.999
HR-HPVsc excluding HPV163 (3.8)14 (5.9)0.52 (0.14–1.96)0.33>0.999
NonHR HPV types8 (10.0)21 (8.8)1.21 (0.51–2.86)0.66>0.999
Any α HPV12 (15.0)35 (14.6)0.98 (0.46–2.08)0.96>0.999
  • aOne control had missing α HPV exposure and thus was excluded from these analyses.

  • bOR and 95% CI were estimated from CLR models adjusted for smoking, alcohol consumption, and study cohort.

  • cHigh-risk (HR) oncogenic HPVs include HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59.

  • dPermutated P values were calculated to account for multiple comparisons (see Material and Methods).